• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Aethlon Medical Inc.

    6/4/26 9:00:38 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care
    Get the next $AEMD alert in real time by email
    424B5 1 aethlon_424b5.htm PROSPECTUS
    PROSPECTUS SUPPLEMENT (To Prospectus Dated January 2, 2026) As Filed

    Pursuant to Rule 424(b)(5)

    Registration No. 333-292405

     

     

    Up to $542,716

     

     A logo for a medical company

Description automatically generated

     

    Common Stock

     

    This amendment to the prospectus supplement (“Amendment No. 1”): amends the prospectus supplement dated January 2, 2026 (the “Original ATM Prospectus Supplement”), to the accompanying base prospectus, dated January 2, 2026 (the “Base Prospectus” and, collectively with the Original ATM Prospectus Supplement, the “Prospectus”) filed as a part of our effective registration statement on Form S-3 (File No. 333-292405) relating to the offer and sale from time to time of common stock, par value $0.001 through or to H.C. Wainwright & Co., LLC, or Wainwright, acting as sales agent or principal. These sales, if any, will be made pursuant to the terms of the at the market offering agreement, or the sales agreement, dated March 24, 2022 and amended on December 19, 2025, between us and Wainwright.

     

    This Amendment No. 1 should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This Amendment No. 1 is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.

     

    We are filing this Amendment No. 1 to update the amount of securities that we are eligible to offer and sell pursuant to General Instruction I.B.6 of Form S-3. As of May 27, 2026, the aggregate market value of our outstanding common stock held by non-affiliates was $7,176,521, based upon 2,337,629 shares of our outstanding common stock held by non-affiliates and a price of $3.07 per share, which is the highest closing sale price of our common stock on the Nasdaq Capital Market within the prior 60 days of this prospectus. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our “public float” (i.e., the aggregate market value of our common stock held by non-affiliates) in any 12 calendar-month period so long as our public float remains below $75.0 million. During the 12 calendar months prior to and including the date of this prospectus (but excluding this offering), we have sold an aggregate of $1,849,457 worth of securities in reliance on General Instruction I.B.6 of Form S-3.

     

    As a result of these limitations and the current public float of our common stock, and in accordance with the terms of the sales agreement with Wainwright after filing this Amendment No.1 we may offer and sell shares of common stock having an aggregate offering price of up to $542,716 from time to time through Wainwright which does not include the shares of common stock having an aggregate sales price of $1,849,457 that were sold pursuant to the Original ATM Prospectus Supplement prior to the filing of this Amendment No. 1.

     

    Sales of our common stock, if any, under this prospectus may be made in sales deemed to be “at the market offerings” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through Nasdaq, or any other existing trading market in the United States for our common stock, sales made to or through a market maker other than on an exchange or otherwise, directly to Wainwright as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or in any other method permitted by law. Wainwright is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Wainwright and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. 

     

     Our common stock is listed on the Nasdaq Capital Market under the symbol “AEMD.” On May 27, 2026, the last reported sale price for our common stock was $3.07 per share.

     

    Investing in our securities involves a high degree of risk. Before buying any of our securities, you should carefully consider the risk factors described in “Risk Factors” on page 20 of the Original ATM Prospectus Supplement and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the Prospectus.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

     

    H.C. Wainwright & Co.

    The date of this prospectus is June 4, 2026.

     

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD

    DatePrice TargetRatingAnalyst
    7/7/2025$1.50Neutral
    H.C. Wainwright
    6/25/2021$5.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gikakis Nicolas

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    4/21/26 5:00:06 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Broenniman Edward G

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    4/21/26 5:00:08 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Rossetti Angela

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    4/21/26 5:00:10 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026

    SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year end March 31, 2026, at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note t

    6/2/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness

    SAN DIEGO, May 21, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology. According to recent reports from the World Health Organization ("WHO") and other public health agencies, the current outbreak has been identified as involving the Bundibugyo strain of

    5/21/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    $AEMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aethlon Medical with a new price target

    H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50

    7/7/25 8:15:50 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously

    6/25/21 6:10:29 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00

    6/1/21 8:48:18 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    SEC Filings

    View All

    Aethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    6/4/26 9:00:39 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Aethlon Medical Inc.

    424B5 - AETHLON MEDICAL INC (0000882291) (Filer)

    6/4/26 9:00:38 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Aethlon Medical Inc.

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    3/17/26 9:15:09 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Leadership Updates

    Live Leadership Updates

    View All

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Financials

    Live finance-specific insights

    View All

    Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026

    SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year end March 31, 2026, at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note t

    6/2/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aethlon Medical, Inc. (Amendment)

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    1/13/22 10:30:14 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Aethlon Medical, Inc.

    SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)

    6/15/21 10:01:32 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    2/22/21 9:53:48 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care